Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
AOTI, Inc. ( (GB:AOTI) ) has provided an update.
AOTI, Inc. announced it has been awarded a five-year extension on its Federal Supply Schedule contract with the U.S. Department of Veterans Affairs, allowing the company to continue providing its TWO2® therapy and NEXA NPWT products to veterans and clinicians within the VA healthcare system. This extension reinforces AOTI’s long-standing partnership with the VA, emphasizing the company’s commitment to promoting health equity and enhancing access to care for veterans with non-healing wounds. The renewal of this contract is expected to strengthen AOTI’s market position and expand its impact within federal healthcare programs.
More about AOTI, Inc.
AOTI, Inc., founded in 2006 and based in Oceanside, California, and Galway, Ireland, is a medical technology company that provides innovative solutions for the treatment of severe and chronic wounds. The company specializes in non-invasive therapies, including its patented Topical Wound Oxygen (TWO2®) therapy, which has been proven to significantly reduce the recurrence of diabetic foot ulcers, hospitalizations, and amputations. AOTI’s products are designed to improve healthcare outcomes and reduce costs, and they have received regulatory approvals across multiple international markets.
YTD Price Performance: -5.88%
Average Trading Volume: 21,699
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £136.1M
See more insights into AOTI stock on TipRanks’ Stock Analysis page.